FasL (human) (multimeric) (rec.)

AdipoGen Life Sciences

FasL (human) (multimeric) (rec.)

10

Research Use Only

0.1 mg/ml

>95%

Tumor necrosis factor ligand superfamily member 6

MultimericFasL™ is a high activity construct in which two trimeric FasL are artificially linked via the collagen domain of ACRP30. This construct very effectively mimics the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development. FasL treatment of stem cells is a robust method for proliferating cells in culture while improving their stemness properties. Treatment with FasL results in a large quantity of Adipose Derived Stem Cells (ASC) of high quality. - Protein. Human FasL (aa 139-281) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. Source: HEK 293 cells. Endotoxin content: <0.02EU/microg purified protein (LAL test; Lonza). Lyophilized. Contains PBS. Binds to human and mouse Fas. Purity: >95% (SDS-PAGE). MultimericFasL™ is a high activity construct in which two trimeric FasL are artificially linked via the collagen domain of ACRP30. This construct very effectively mimics the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development.

2°C to 8°C,-20°C

12352202